SARS-CoV-2 Seroprevalence Among Parturient Women
Abstract Limited data are available for pregnant women affected by SARS-CoV-2. Serological tests are critically important to determine exposure and immunity to SARS-CoV-2 within both individuals and populations. We completed SARS-CoV-2 serological testing of 1,293 parturient women at two centers in Philadelphia from April 4 to June 3, 2020. We tested 834 pre-pandemic samples collected in 2019 and 15 samples from COVID-19 recovered donors to validate our assay, which has a ∼1% false positive rate. We found 80/1,293 (6.2%) of parturient women possessed IgG and/or IgM SARS-CoV-2-specific antibodies. We found race/ethnicity differences in seroprevalence rates, with higher rates in Black/non-Hispanic and Hispanic/Latino women. Of the 72 seropositive women who also received nasopharyngeal polymerase chain reaction testing during pregnancy, 46 (64%) were positive. Continued serologic surveillance among pregnant women may inform perinatal clinical practices and can potentially be used to estimate seroprevalence within the community.One Sentence Summary Six percent of pregnant women delivering from April 4 to June 3, 2020 had serological evidence of exposure to SARS-CoV-2 with notable race/ethnicity differences in seroprevalence rates..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
bioRxiv.org - (2022) vom: 02. Nov. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Flannery, Dustin D. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2020.07.08.20149179 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI018330177 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI018330177 | ||
| 003 | DE-627 | ||
| 005 | 20230429100536.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200713s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.07.08.20149179 |2 doi | |
| 035 | |a (DE-627)XBI018330177 | ||
| 035 | |a (biorXiv)10.1101/2020.07.08.20149179 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Flannery, Dustin D. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 Seroprevalence Among Parturient Women |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Limited data are available for pregnant women affected by SARS-CoV-2. Serological tests are critically important to determine exposure and immunity to SARS-CoV-2 within both individuals and populations. We completed SARS-CoV-2 serological testing of 1,293 parturient women at two centers in Philadelphia from April 4 to June 3, 2020. We tested 834 pre-pandemic samples collected in 2019 and 15 samples from COVID-19 recovered donors to validate our assay, which has a ∼1% false positive rate. We found 80/1,293 (6.2%) of parturient women possessed IgG and/or IgM SARS-CoV-2-specific antibodies. We found race/ethnicity differences in seroprevalence rates, with higher rates in Black/non-Hispanic and Hispanic/Latino women. Of the 72 seropositive women who also received nasopharyngeal polymerase chain reaction testing during pregnancy, 46 (64%) were positive. Continued serologic surveillance among pregnant women may inform perinatal clinical practices and can potentially be used to estimate seroprevalence within the community.One Sentence Summary Six percent of pregnant women delivering from April 4 to June 3, 2020 had serological evidence of exposure to SARS-CoV-2 with notable race/ethnicity differences in seroprevalence rates. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Gouma, Sigrid |e verfasserin |4 aut | |
| 700 | 1 | |a Dhudasia, Miren B. |e verfasserin |4 aut | |
| 700 | 1 | |a Mukhopadhyay, Sagori |e verfasserin |4 aut | |
| 700 | 1 | |a Pfeifer, Madeline R. |e verfasserin |4 aut | |
| 700 | 1 | |a Woodford, Emily C. |e verfasserin |4 aut | |
| 700 | 1 | |a Gerber, Jeffrey S. |e verfasserin |4 aut | |
| 700 | 1 | |a Arevalo, Claudia P. |e verfasserin |4 aut | |
| 700 | 1 | |a Bolton, Marcus J. |e verfasserin |4 aut | |
| 700 | 1 | |a Weirick, Madison E. |e verfasserin |4 aut | |
| 700 | 1 | |a Goodwin, Eileen C. |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Elizabeth M. |e verfasserin |4 aut | |
| 700 | 1 | |a Greenplate, Allison R. |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Justin |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Nicholas |e verfasserin |4 aut | |
| 700 | 1 | |a Pattekar, Ajinkya |e verfasserin |4 aut | |
| 700 | 1 | |a Dougherty, Jeanette |e verfasserin |4 aut | |
| 700 | 1 | |a Kuthuru, Oliva |e verfasserin |4 aut | |
| 700 | 1 | |a Mathew, Divij |e verfasserin |4 aut | |
| 700 | 1 | |a Baxter, Amy E. |e verfasserin |4 aut | |
| 700 | 1 | |a Vella, Laura A. |e verfasserin |4 aut | |
| 700 | 1 | |a Weaver, JoEllen |e verfasserin |4 aut | |
| 700 | 1 | |a Verma, Anurag |e verfasserin |4 aut | |
| 700 | 1 | |a Leite, Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Morris, Jeffrey S. |e verfasserin |4 aut | |
| 700 | 1 | |a Rader, Daniel J. |e verfasserin |4 aut | |
| 700 | 1 | |a Elovitz, Michal A. |e verfasserin |4 aut | |
| 700 | 1 | |a Wherry, E. John |e verfasserin |4 aut | |
| 700 | 1 | |a Puopolo, Karen M. |e verfasserin |4 aut | |
| 700 | 1 | |a Hensley, Scott E. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2022) vom: 02. Nov. |
| 773 | 1 | 8 | |g year:2022 |g day:02 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.07.08.20149179 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 02 |c 11 | ||